BCSF Stock Analysis: Bain Capital Specialty | NYSE
Asset Management | NYSE, USA | Market Cap: 820m USD | 12M Return: -3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.32M
EPS Trend: -67.3%
Qual. Beats: 0
Rev. Trend: -61.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bain Capital Specialty Finance, Inc. (BCSF) is a publicly traded business development company (BDC) that provides direct loans to U.S. middle-market companies. It focuses primarily on senior-secured credit instruments, including first lien, stretch senior, unitranche, second lien, and mezzanine debt, along with selective junior securities and secondary debt purchases. The company generally targets borrowers with EBITDA between $10 million and $150 million.
As a BDC, BCSF operates under a regulatory framework that requires it to distribute the majority of its taxable earnings to shareholders, making dividend yield a key component of its investment profile. The firm benefits from Bain Capitals broader credit platform, which provides sourcing, underwriting, and portfolio management capabilities to middle-market lenders, a market segment that often has limited access to traditional bank financing.
- Net interest margin expands as base rates remain elevated
- Middle-market credit quality holds with low non-accrual rate
- Private credit competition pressures new deal spreads
| Net Income: 73.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: -296.5% < 20% (prev 37.83%; Δ -334.3% < -1%) |
| CFO/TA 0.03 > 3% & CFO 90.7m > Net Income 73.6m |
| Net Debt (1.44b) to EBITDA (97.5m): 14.75 < 3 |
| Current Ratio: 0.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.9m) vs 12m ago 0.30% < -2% |
| Gross Margin: 61.16% > 18% (prev 63.56%; Δ -2.40% > 0.5%) |
| Asset Turnover: 7.50% > 50% (prev 7.84%; Δ -0.34% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBIT TTM 97.5m / Interest Expense TTM 81.9m) |
| A: -0.22 (Total Current Assets 16.9m - Total Current Liabilities 600.0m) / Total Assets 2.60b |
| B: -0.03 (Retained Earnings -67.6m / Total Assets 2.60b) |
| C: 0.04 (EBIT TTM 97.5m / Avg Total Assets 2.62b) |
| D: 0.73 (Book Value of Equity 1.09b / Total Liabilities 1.51b) |
| Altman-Z'' = -0.54 = B |
As of July 08, 2026, the stock is trading at USD 12.69 with a total of 216,716 shares traded. Over the past week, the price has changed by +1.52%, over one month by +2.08%, over three months by +5.02% and over the past year by -2.95%.
Current recommended Stop Loss: 12.20 (which is 3.9% or 1.6 ATR below the current price).
Bain Capital Specialty has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold BCSF.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.8 | 9% |
P/E Trailing = 11.0877
P/E Forward = 10.1112
P/S = 3.0081
P/B = 0.7492
P/EG = 1.0474
Revenue TTM = 196.7m USD
EBIT TTM = 97.5m USD
EBITDA TTM = 97.5m USD
Long Term Debt = unknown (none)
Short Term Debt = 600.0m USD (from shortTermDebt, last fiscal year)
Debt = 1.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.44b USD (calculated: Debt 1.45b - CCE 16.6m)
Enterprise Value = 2.26b USD (819.9m + Debt 1.45b - CCE 16.6m)
Interest Coverage Ratio = 1.19 (Ebit TTM 97.5m / Interest Expense TTM 81.9m)
EV/FCF = 24.89x (Enterprise Value 2.26b / FCF TTM 90.7m)
FCF Yield = 4.02% (FCF TTM 90.7m / Enterprise Value 2.26b)
FCF Margin = 46.13% (FCF TTM 90.7m / Revenue TTM 196.7m)
Net Margin = 37.42% (Net Income TTM 73.6m / Revenue TTM 196.7m)
Gross Margin = 61.16% ((Revenue TTM 196.7m - Cost of Revenue TTM 76.4m) / Revenue TTM)
Gross Margin QoQ = 72.55% (prev 61.60%)
Tobins Q-Ratio = 0.87 (Enterprise Value 2.26b / Total Assets 2.60b)
Interest Expense / Debt = 5.63% (Interest Expense 81.9m / Debt 1.45b)
Taxrate = 4.64% (3.58m / 77.2m)
NOPAT = 93.0m (EBIT 97.5m * (1 - 4.64%))
Current Ratio = 0.03 (Total Current Assets 16.9m / Total Current Liabilities 600.0m)
Debt / Equity = 1.33 (Debt 1.45b / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 14.75 (Net Debt 1.44b / EBITDA 97.5m)
Debt / FCF = 15.85 (Net Debt 1.44b / FCF TTM 90.7m)
Total Stockholder Equity = 1.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.81% (Net Income 73.6m / Total Assets 2.60b)
RoE = 6.57% (Net Income TTM 73.6m / Total Stockholder Equity 1.12b)
RoCE = 4.87% (EBIT 97.5m / Capital Employed (Total Assets 2.60b - Current Liab 600.0m))
RoIC = 2.96% (NOPAT 93.0m / Invested Capital 3.14b)
WACC = 6.49% (E(819.9m)/V(2.27b) * Re(8.48%) + D(1.45b)/V(2.27b) * Rd(5.63%) * (1-Tc(0.05)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈100.0m ; Y1≈87.7m ; Y5≈70.9m
[DCF] Fair Price = N/A (negative equity: EV 1.14b - Net Debt 1.44b = -300.5m; debt exceeds intrinsic value)
EPS Correlation: -67.34 | EPS CAGR: -4.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: -61.69 | Revenue CAGR: -4.01% | SUE: -0.60 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=+5.36% | Revisions=+40% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=+9.70% | Revisions=+40% | Analysts=3
EPS current Year (2026-12-31): EPS=1.69 | Chg30d=+4.33% | Revisions=+40% | GrowthEPS=-10.3% | GrowthRev=-6.0%
EPS next Year (2027-12-31): EPS=1.48 | Chg30d=+0.68% | Revisions=+40% | GrowthEPS=-12.1% | GrowthRev=-5.1%
[Analyst] Revisions Ratio: +73% (up=8, down=0)